Body Mass Index as a Risk Factor for Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Víctor Juan  Vera-Ponce; Joan A.  Loayza-Castro; Luisa Erika Milagros Vásquez-Romero; Fiorella Elvira  Zuzunaga-Montoya

doi:10.6000/1929-6029.2024.13.11

Authors

Víctor Juan Vera-Ponce Instituto de Investigación de Enfermedades Tropicales, Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú and Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú
Joan A. Loayza-Castro Instituto de Investigación de Enfermedades Tropicales, Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú and Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú
Luisa Erika Milagros Vásquez-Romero Instituto de Investigación de Enfermedades Tropicales, Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú and Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú
Fiorella Elvira Zuzunaga-Montoya Instituto de Investigación de Enfermedades Tropicales, Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú and Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú

DOI:

https://doi.org/10.6000/1929-6029.2024.13.11

Keywords:

Lymphoma, B-cell, Body Weights and Measures, Body Mass Index, Systematic Review (Source: MeSH NLM)

Abstract

Introduction: Given the increasing prevalence of obesity, as measured by the Body Mass Index (BMI), and the significant impact of Diffuse Large B-cell lymphoma (DLBCL) on global health, it is crucial to update our understanding of the relationship between BMI and DLBCL.

Objective: to carry out a systematic review (SR) with meta-analysis to determine the association between DLBCL and BMI

Methods: This study is a systematic review and meta-analysis following the PRISMA guidelines. It searched PubMed/Medline, SCOPUS, Web of Science, and EMBASE. The inclusion criteria were primary observational studies involving adults with DLBCL confirmed by biopsy. Exclusions were non-peer-reviewed materials and studies without inferential statistics. The findings of the study are presented as association measures such as relative risks (RR), accompanied by their corresponding 95% confidence intervals (95% CI).

Results: From 451 articles, 13 met the criteria for inclusion. The included studies, conducted between 2002 and 2013 in various countries, showed varied follow-up periods and sample sizes. The meta-analysis revealed that individuals with high BMI have a 1.31 times higher risk of developing DLBCL than those with lower BMI (RR: 1.31; 95% CI 1.07, 1.61). The heterogeneity among studies was moderate.

Conclusions: The study confirms an association between higher BMI and the increased risk of developing DLBCL. This finding underscores the need to explore further how obesity, chronic inflammation, and the development and progression of DLBCL are interconnected. Understanding this area could significantly reduce DLBCL incidence and improve patient outcomes.

References

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues - IARC, https://www.iarc.who.int/news-events/who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues-2/ (accessed 11 June 2023).

Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology 2018; 50: 74-87. https://doi.org/10.1016/j.pathol.2017.09.006 DOI: https://doi.org/10.1016/j.pathol.2017.09.006

Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology 2018; 4: 1553-1568. https://doi.org/10.1200/JCO.2018.36.15_suppl.1568 DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.1568

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians 2019; 69: 7-34. https://doi.org/10.3322/caac.21551 DOI: https://doi.org/10.3322/caac.21551

SEER Cancer Statistics Review, 1975-2017. SEER, https://seer.cancer.gov/csr/1975_2017/index.html (accessed 11 June 2023).

Diumenjo MC, Abriata G, Forman D, et al. The burden of non-Hodgkin lymphoma in Central and South America. Cancer Epidemiol 2016; 44 Suppl 1: S168-S177. https://doi.org/10.1016/j.canep.2016.05.008 DOI: https://doi.org/10.1016/j.canep.2016.05.008

Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin’s and Hodgkin’s lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011; 47: 2422-2430. https://doi.org/10.1016/j.ejca.2011.06.029 DOI: https://doi.org/10.1016/j.ejca.2011.06.029

Castillo JJ, Ingham RR, Reagan JL, et al. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. Clin Lymphoma Myeloma Leuk 2014; 14: 122-130. https://doi.org/10.1016/j.clml.2013.10.005 DOI: https://doi.org/10.1016/j.clml.2013.10.005

Wang Z, Luo S, Zhao X. The Prognostic Impact of Body Mass Index in Patients with Diffuse Large B-Cell Lymphoma: A Meta-Analysis. Nutr Cancer 2021; 73: 2336-2346. https://doi.org/10.1080/01635581.2020.1823437 DOI: https://doi.org/10.1080/01635581.2020.1823437

Hidayat K, Li H-J, Shi B-M. Anthropometric factors and non-Hodgkin’s lymphoma risk: systematic review and meta-analysis of prospective studies. Crit Rev Oncol Hematol 2018; 129: 113-123. https://doi.org/10.1016/j.critrevonc.2018.05.018 DOI: https://doi.org/10.1016/j.critrevonc.2018.05.018

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097. https://doi.org/10.1371/journal.pmed.1000097 DOI: https://doi.org/10.1371/journal.pmed.1000097

Ottawa Hospital Research Institute, https://www.ohri.ca/ programs/clinical_epidemiology/oxford.asp (accessed 11 July 2022).

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. StatMed 2002; 21: 1539-1558. https://doi.org/10.1002/sim.1186 DOI: https://doi.org/10.1002/sim.1186

Cochrane Handbook for Systematic Reviews of Interventions, https://training.cochrane.org/handbook (accessed 27 November 2021).

Cerhan JR, Janney CA, Vachon CM, et al. Anthropometric characteristics, physical activity, and risk of non-Hodgkin’s lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol 2002; 156: 527-535. https://doi.org/10.1093/aje/kwf082 DOI: https://doi.org/10.1093/aje/kwf082

Lim U, Morton LM, Subar AF, et al. Alcohol, smoking, and body size in relation to incident Hodgkin’s and non-Hodgkin’s lymphoma risk. Am J Epidemiol 2007; 166: 697-708. https://doi.org/10.1093/aje/kwm122 DOI: https://doi.org/10.1093/aje/kwm122

Maskarinec G, Erber E, Gill J, et al. Overweight and Obesity at Different Times in Life as Risk Factors for Non-Hodgkin’s Lymphoma: The Multiethnic Cohort. Cancer Epidemiology, Biomarkers & Prevention 2008; 17: 196-203. https://doi.org/10.1158/1055-9965.EPI-07-0716 DOI: https://doi.org/10.1158/1055-9965.EPI-07-0716

Lu Y, Prescott J, Sullivan-Halley J, et al. Body Size, Recreational Physical Activity, and B-Cell Non-Hodgkin Lymphoma Risk Among Women in the California Teachers Study. Am J Epidemiol 2009; 170: 1231-1240. https://doi.org/10.1093/aje/kwp268 DOI: https://doi.org/10.1093/aje/kwp268

Pylypchuk RD, Schouten LJ, Goldbohm RA, et al. Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study. Am J Epidemiol 2009; 170: 297-307. https://doi.org/10.1093/aje/kwp123 DOI: https://doi.org/10.1093/aje/kwp123

Nagel G, Stocks T, Späth D, et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol 2012; 91: 1519-1531. https://doi.org/10.1007/s00277-012-1489-z DOI: https://doi.org/10.1007/s00277-012-1489-z

Kabat GC, Kim MY, Jean-Wactawski-Wende null, et al. Anthropometric factors, physical activity, and risk of non-Hodgkin’s lymphoma in the Women’s Health Initiative. Cancer Epidemiol 2012; 36: 52-59. https://doi.org/10.1016/j.canep.2011.05.014 DOI: https://doi.org/10.1016/j.canep.2011.05.014

Britton JA, Khan AE, Rohrmann S, et al. Anthropometric characteristics and non-Hodgkin’s lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica 2008; 93: 1666-1677. https://doi.org/10.3324/haematol.13078 DOI: https://doi.org/10.3324/haematol.13078

Bertrand KA, Giovannucci E, Zhang SM, et al. A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res (Phila) 2013; 6: 864-873. https://doi.org/10.1158/1940-6207.CAPR-13-0132 DOI: https://doi.org/10.1158/1940-6207.CAPR-13-0132

Troy JD, Hartge P, Weissfeld JL, et al. Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Epidemiol 2010; 171: 1270-1281. https://doi.org/10.1093/aje/kwq085 DOI: https://doi.org/10.1093/aje/kwq085

Patel AV, Diver WR, Teras LR, et al. Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 2013; 54: 1221-1227. https://doi.org/10.3109/10428194.2012.742523 DOI: https://doi.org/10.3109/10428194.2012.742523

Murphy F, Kroll ME, Pirie K, et al. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer 2013; 108: 2390-2398. https://doi.org/10.1038/bjc.2013.159 DOI: https://doi.org/10.1038/bjc.2013.159

Chang ET, Hjalgrim H, Smedby KE, et al. Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst 2005; 97: 210-218. https://doi.org/10.1093/jnci/dji012 DOI: https://doi.org/10.1093/jnci/dji012

Rush E. WHO. World Health Organization (WHO) Expert Consultation: appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157-163. The Lancet 2004; 363: 157-163. https://doi.org/10.1016/S0140-6736(03)15268-3 DOI: https://doi.org/10.1016/S0140-6736(03)15268-3

Ursø B, Ilondo MM, Holst PA, et al. IRS-4 mediated mitogenic signalling by insulin and growth hormone in LB cells, a murine T-cell lymphoma devoid of IGF-I receptors. Cell Signal 2003; 15: 385-394. https://doi.org/10.1016/S0898-6568(02)00113-4 DOI: https://doi.org/10.1016/S0898-6568(02)00113-4

Syrigos KN, Salgami E, Karayiannakis AJ, et al. Prognostic significance of soluble adhesion molecules in Hodgkin’s disease. Anticancer Res 2004; 24: 1243-1247.